August 2026– date –
-
Understanding Regenerative Medicine: Distinguishing PMDA-Approved Treatments from Research in Japan
GINZA YR CLINIC Japan Overview Regenerative medicine, encompassing cell therapies, stem cell research, and tissue engineering, aims to restore damaged tissues and organs. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) is... -
Allogene’s Off-the-Shelf CAR T Cema-Cel Secures FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
OncLive USA Overview Allogene Therapeutics' off-the-shelf anti-CD19 CAR T-cell therapy, cemacabtagene ansegedleucel (cema-cel), received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for first-line consoli... -
FDA Regenerative Medicine Approvals Accelerate: Record 8 Approvals in 2024, RMAT Designations Signal Continued Momentum
Pharmaceutical Technology USA Overview U.S. FDA approvals for regenerative medicine products have accelerated significantly, reaching a record eight approvals in 2024. The surge in Regenerative Medicine Advanced Therapy (RMAT) designatio... -
Allogene’s Off-the-Shelf CAR T, Cema-Cel, Earns FDA RMAT and Fast Track for High-Risk LBCL First-Line Consolidation
Allogene Therapeutics, Inc. USA Overview Allogene Therapeutics has secured FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T-cell therapy, cemacabtagene ansegedleucel (... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
FDA Clarifies Regenerative Medicine Regulations: Strategic Use of RMAT Designation and HCT/P Classification to Accelerate Development
Global MedTech Expert USA Overview The U.S. FDA has detailed its Regenerative Medicine Advanced Therapy (RMAT) designation, offering a fast-track development framework for cell and gene therapies targeting serious or life-threatening dis... -
EU AI Act Extends High-Risk System Compliance Deadline to 2027, While Transparency Mandates Loom
Ethisphere Europe Overview The European Union has postponed the compliance deadline for standalone high-risk AI systems under its landmark AI Act, pushing it from August 2, 2026, to December 2, 2027. This extension, introduced via Regula... -
OpenAI Commits $150M to Enterprise AI Deployment with Forward Deployed Engineers Embedded in Client Operations
MarketScale USA Overview OpenAI has launched a $150 million enterprise partner program and established OpenAI Deployment Co., a new services firm, to accelerate AI implementation for businesses. This initiative embeds "forward deployed e... -
OpenAI Launches “OpenAI Presence,” a Managed Enterprise Platform for Governed AI Agents in High-Stakes Workflows
OpenAI USA Overview OpenAI has launched "OpenAI Presence," a managed enterprise platform designed for building, deploying, operating, and continuously improving governed AI agents in high-volume, high-stakes workflows. Presence integrate... -
EU AI Act Reshapes Global AI Development: A Mandate for Proactive Transparency and Risk Management
Quantal AI USA, Europe Overview The EU AI Act, the world's first comprehensive AI law, now compels global AI product builders to integrate transparency, governance, and robust risk management from the initial design phases. This extrater...
